LIVIVO - Search results -

Search results

Result 1 - 10 of total 291

Search options

Article ; Online: Letter to the Editor: Use of Pregenomic Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen to Predict Cure of Hepatitis B Virus Infection.

Chan, Henry Lik-Yuen

2021 Volume 73, Issue 2, Page(s) 870

MeSH term(s)	Hepatitis B/drug therapy ; Hepatitis B Core Antigens ; Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Humans ; RNA
Chemical Substances	Hepatitis B Core Antigens ; Hepatitis B e Antigens ; RNA (63231-63-0)
Language	English
Publishing date	2021-01-21
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	604603-4
ISSN	1527-3350 ; 0270-9139
ISSN (online)	1527-3350
ISSN	0270-9139
DOI	10.1002/hep.31469
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1660: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Debate settled for elevated alanine aminotransferase in hepatitis B?

Chan, Henry Lik-Yuen

The Lancet. Infectious diseases

2021 Volume 21, Issue 6, Page(s) 750–751

MeSH term(s)	Alanine Transaminase ; Double-Blind Method ; Hepatitis B ; Hepatitis B virus ; Hepatitis B, Chronic ; Humans ; Tenofovir
Chemical Substances	Tenofovir (99YXE507IL) ; Alanine Transaminase (EC 2.6.1.2)
Language	English
Publishing date	2021-01-29
Publishing country	United States
Document type	Journal Article ; Comment
ZDB-ID	2061641-7
ISSN	1474-4457 ; 1473-3099
ISSN (online)	1474-4457
ISSN	1473-3099
DOI	10.1016/S1473-3099(20)30682-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5743: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Editorial: a baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients-same score, different outcomes. Author's Reply.

Chan, Henry Lik Yuen

Alimentary pharmacology & therapeutics

2018 Volume 48, Issue 8, Page(s) 876–877

MeSH term(s)	Hepatitis B e Antigens ; Hepatitis B, Chronic ; Humans ; Interferon-alpha ; Polyethylene Glycols ; Recombinant Proteins
Chemical Substances	Hepatitis B e Antigens ; Interferon-alpha ; Recombinant Proteins ; Polyethylene Glycols (3WJQ0SDW1A) ; peginterferon alfa-2a (Q46947FE7K)
Language	English
Publishing date	2018-09-18
Publishing country	England
Document type	Editorial ; Comment
ZDB-ID	639012-2
ISSN	1365-2036 ; 0269-2813 ; 0953-0673
ISSN (online)	1365-2036
ISSN	0269-2813 ; 0953-0673
DOI	10.1111/apt.14961
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2206: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy.

Chan, Henry Lik Yuen

Journal of gastroenterology and hepatology

2018 Volume 34, Issue 3, Page(s) 501–506

Abstract: Nucleos(t)ide analogs (NAs) are effective, safe, and convenient antiviral therapy to suppress replication of hepatitis B virus, which can be translated into improved long-term outcome of chronic hepatitis B patients. The current recommended first-line ... ...

Abstract	Nucleos(t)ide analogs (NAs) are effective, safe, and convenient antiviral therapy to suppress replication of hepatitis B virus, which can be translated into improved long-term outcome of chronic hepatitis B patients. The current recommended first-line NAs, namely, entecavir and tenofovir, are largely free from problems of drug resistance. Nonetheless, there are still a few challenges in the era of NA. First, the risk of hepatocellular carcinoma can only be reduced but not eliminated, particularly among cirrhotic patients. For cirrhotic patients who have persistent low-level viremia on NA, that is, partial responders, the risk of hepatocellular carcinoma is higher than those with complete viral suppression. The best strategy to manage partial responders to entecavir or tenofovir is uncertain. Second, immune-tolerant patients are very difficult to treat with NA. A significant proportion of immune-tolerant patients will have detectable viremia despite a few years of continuous NA treatment, and the rate of hepatitis B e-antigen seroconversion is very low. Third, most patients need long-term treatment as NA cannot eliminate covalently closed circular DNA in the hepatocytes. Some patients can consider stop NA according to treatment guidelines, but viral and clinical relapses often occur after treatment cessation. There is no concrete consensus on when one should stop NA in a hepatitis B e-antigen-negative patient among different treatment guidelines. New biomarkers such as hepatitis B surface antigen level can be used to select patients to stop NA, but the data are still preliminary.
MeSH term(s)	Antiviral Agents/administration & dosage ; Antiviral Agents/therapeutic use ; Biomarkers/blood ; Carcinoma, Hepatocellular/etiology ; Carcinoma, Hepatocellular/prevention & control ; Guanine/administration & dosage ; Guanine/analogs & derivatives ; Guanine/therapeutic use ; Hepatitis B/complications ; Hepatitis B/diagnosis ; Hepatitis B/drug therapy ; Hepatitis B/immunology ; Hepatitis B e Antigens/blood ; Humans ; Immune Tolerance ; Liver Neoplasms/etiology ; Liver Neoplasms/prevention & control ; Nucleotides/administration & dosage ; Nucleotides/therapeutic use ; Tenofovir/administration & dosage ; Tenofovir/therapeutic use ; Withholding Treatment
Chemical Substances	Antiviral Agents ; Biomarkers ; Hepatitis B e Antigens ; Nucleotides ; entecavir (5968Y6H45M) ; Guanine (5Z93L87A1R) ; Tenofovir (99YXE507IL)
Language	English
Publishing date	2018-11-22
Publishing country	Australia
Document type	Journal Article ; Review
ZDB-ID	632882-9
ISSN	1440-1746 ; 0815-9319
ISSN (online)	1440-1746
ISSN	0815-9319
DOI	10.1111/jgh.14534
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2180: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 299: Show issues

Order via subito

Details ▾

Article ; Online: Hepatitis B Core-Related Antigen: From Virology to Clinical Application.

Lee, Hye Won / Ahn, Sang Hoon / Chan, Henry Lik-Yuen

Seminars in liver disease

2021 Volume 41, Issue 2, Page(s) 182–190

Abstract: Hepatitis B core-related antigen (HBcrAg) is a composite measure of the serum levels of hepatitis B e antigen, hepatitis B core antigen, and a 22-kDa precore protein. It has been shown to reflect the level and transcriptional activity of covalently ... ...

Abstract	Hepatitis B core-related antigen (HBcrAg) is a composite measure of the serum levels of hepatitis B e antigen, hepatitis B core antigen, and a 22-kDa precore protein. It has been shown to reflect the level and transcriptional activity of covalently closed circular DNA in the liver. Longitudinal cohort studies have improved our understanding of the role of this novel viral marker in the natural history of chronic hepatitis B. HBcrAg kinetics reflect the response to peginterferon, and its role in defining guidelines for stopping peginterferon therapy has been evaluated. HBcrAg is a marker of intrahepatic viral activity, which may influence the risk of hepatocellular carcinoma. In this article, we review the virology and role of HBcrAg in defining phases of chronic hepatitis B. Furthermore, the function of HBcrAg in predicting treatment outcomes and its role in monitoring response to novel antiviral agents will be discussed.
MeSH term(s)	Antiviral Agents/therapeutic use ; Biomarkers ; DNA, Viral ; Hepatitis B Core Antigens/therapeutic use ; Hepatitis B Surface Antigens ; Hepatitis B virus/genetics ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/drug therapy ; Humans ; Liver Neoplasms/drug therapy ; Longitudinal Studies
Chemical Substances	Antiviral Agents ; Biomarkers ; DNA, Viral ; Hepatitis B Core Antigens ; Hepatitis B Surface Antigens
Language	English
Publishing date	2021-05-06
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	603177-8
ISSN	1098-8971 ; 0272-8087
ISSN (online)	1098-8971
ISSN	0272-8087
DOI	10.1055/s-0041-1723088
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1752: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Unresolved issues of immune tolerance in chronic hepatitis B.

Lee, Hye Won / Chan, Henry Lik-Yuen

Journal of gastroenterology

2020 Volume 55, Issue 4, Page(s) 383–389

Abstract: During the natural course of chronic hepatitis B virus infection, immune-tolerant phase is characterized by high viral replication, the presence of HBV e antigen (HBeAg), and normal or minimally elevated serum alanine aminotransferase. Immune-tolerant ... ...

Abstract	During the natural course of chronic hepatitis B virus infection, immune-tolerant phase is characterized by high viral replication, the presence of HBV e antigen (HBeAg), and normal or minimally elevated serum alanine aminotransferase. Immune-tolerant phase is usually regarded as a benign course of the disease. International guidelines recommend observation rather than treatment during immune-tolerant phase. In this article, we review unresolved issues related to the definition of true immune-tolerant phase and the benefit of antiviral treatment. Defining true immune-tolerant phase requires a careful approach and long-term follow-up. In previous studies, many patients were misclassified as being immune-tolerant phase. Noninvasive methods of assessing fibrosis are warranted for patients in the immune-tolerant phase. Yet, there has been controversy over the benefit and harm of antiviral treatment for immune-tolerant phase patients. Thus, further larger scale studies are needed to investigate the prognosis of patients in true immune-tolerant phase and their need for antiviral therapy.
MeSH term(s)	Alanine Transaminase/blood ; Antiviral Agents/therapeutic use ; Biomarkers/blood ; Biopsy ; Conservative Treatment ; DNA, Viral/blood ; Hepatitis B Surface Antigens/blood ; Hepatitis B virus ; Hepatitis B, Chronic/blood ; Hepatitis B, Chronic/immunology ; Hepatitis B, Chronic/therapy ; Humans ; Immune Tolerance ; Liver/pathology
Chemical Substances	Antiviral Agents ; Biomarkers ; DNA, Viral ; Hepatitis B Surface Antigens ; Alanine Transaminase (EC 2.6.1.2)
Language	English
Publishing date	2020-02-03
Publishing country	Japan
Document type	Journal Article ; Review
ZDB-ID	1186495-3
ISSN	1435-5922 ; 0944-1174
ISSN (online)	1435-5922
ISSN	0944-1174
DOI	10.1007/s00535-020-01665-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 620: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Letter: systematic review with meta-analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B.

Yip, Terry Cheuk-Fung / Wong, Grace Lai-Hung / Wong, Vincent Wai-Sun / Chan, Henry Lik-Yuen

Alimentary pharmacology & therapeutics

2022 Volume 55, Issue 5, Page(s) 616–617

MeSH term(s)	Hepatitis B Surface Antigens ; Hepatitis B virus ; Hepatitis B, Chronic/drug therapy ; Humans
Chemical Substances	Hepatitis B Surface Antigens
Language	English
Publishing date	2022-02-09
Publishing country	England
Document type	Letter ; Comment
ZDB-ID	639012-2
ISSN	1365-2036 ; 0269-2813 ; 0953-0673
ISSN (online)	1365-2036
ISSN	0269-2813 ; 0953-0673
DOI	10.1111/apt.16758
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2206: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Reply to: "NAFLD and beneficial effects of lifestyle intervention: Defining the meat of the matter".

Wong, Vincent Wai-Sun / Chan, Henry Lik-Yuen

Journal of hepatology

2019 Volume 70, Issue 6, Page(s) 1304

MeSH term(s)	Humans ; Life Style ; Meat ; Non-alcoholic Fatty Liver Disease ; Weight Loss
Language	English
Publishing date	2019-03-02
Publishing country	Netherlands
Document type	Letter ; Research Support, Non-U.S. Gov't ; Comment
ZDB-ID	605953-3
ISSN	1600-0641 ; 0168-8278
ISSN (online)	1600-0641
ISSN	0168-8278
DOI	10.1016/j.jhep.2019.02.008
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2027: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A new biomarker panel for differential diagnosis of cholangiocarcinoma: Results from an exploratory analysis.

Köhler, Bruno / Bes, Marta / Chan, Henry Lik-Yuen / Esteban, Juan Ignacio / Piratvisuth, Teerha / Sukeepaisarnjaroen, Wattana / Tanwandee, Tawesak / Thongsawat, Satawat / Mang, Anika / Morgenstern, David / Swiatek-de Lange, Magdalena / Dayyani, Farshid

The International journal of biological markers

2024 , Page(s) 3936155241235185

Abstract: Introduction: Diagnosis of cholangiocarcinoma (CCA) can be challenging due to unclear imaging criteria and difficulty obtaining adequate tissue biopsy. Although serum cancer antigen 19-9 and carcinoembryonic antigen have been proposed as potential ... ...

Abstract	Introduction: Diagnosis of cholangiocarcinoma (CCA) can be challenging due to unclear imaging criteria and difficulty obtaining adequate tissue biopsy. Although serum cancer antigen 19-9 and carcinoembryonic antigen have been proposed as potential diagnostic aids, their use remains limited by insufficient sensitivity and specificity. This exploratory analysis aimed to identify individual- and combinations of serum biomarkers to distinguish CCA from hepatocellular carcinoma (HCC) and chronic liver disease (CLD) controls using samples from a published study. Methods: This prospective, multicenter, case-control study included patients aged ≥18 years at high-risk of HCC. Serum and ethylene diamine tetraacetic acid-plasma samples were collected prior to any treatment and confirmed diagnosis of HCC or CCA. Fourteen biomarkers (measured by electrochemiluminescence immunoassays or enzyme-linked immunosorbent assays) were subjected to univariate analysis and 13 included in a multivariate analysis (per selected combinations and exhaustive search). Results: Overall, 55 CCA, 306 HCC, and 733 CLD control samples were analyzed. For distinguishing CCA from HCC, alpha-fetoprotein and matrix metalloproteinase-2 (MMP-2) showed the best individual performance (area under the curve (AUC) 86.6% and 84.4%, respectively); tissue inhibitor of metalloproteinase-1 (TIMP-1) was most able to distinguish CCA from CLD (AUC 94.5%) and from HCC + CLD (AUC 88.6%). The combination of MMP-2 and TIMP-1 was the best-performing two-marker panel, with AUC >90% for all comparisons. Conclusion: MMP-2 and TIMP-1 are promising biomarkers that could support differential diagnosis of CCA. Incorporating these assays into the diagnostic algorithm could provide additional diagnostic information in a non-invasive, rapid manner, and could supplement existing diagnostic methods.
Language	English
Publishing date	2024-03-28
Publishing country	United States
Document type	Journal Article
ZDB-ID	645113-5
ISSN	1724-6008 ; 0393-6155
ISSN (online)	1724-6008
ISSN	0393-6155
DOI	10.1177/03936155241235185
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2491: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: CAMP-B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance.

Lee, Hye Won / Yip, Terry Cheuk-Fung / Wong, Vincent Wai-Sun / Lim, Young-Suk / Chan, Henry Lik-Yuen / Ahn, Sang Hoon / Wong, Grace Lai-Hung / Choi, Jonggi

Alimentary pharmacology & therapeutics

2024 Volume 59, Issue 10, Page(s) 1223–1235

Abstract: Background: Risk of hepatocellular carcinoma (HCC) persists after hepatitis B surface antigen (HBsAg) seroclearance in patients with chronic hepatitis B (CHB).: Aims: To identify risk factors and construct a predictive model for HCC development.: ... ...

Abstract	Background: Risk of hepatocellular carcinoma (HCC) persists after hepatitis B surface antigen (HBsAg) seroclearance in patients with chronic hepatitis B (CHB). Aims: To identify risk factors and construct a predictive model for HCC development. Methods: We retrospectively analysed patients with CHB with HBsAg seroclearance. Primary outcome was HCC development. Factors identified from a multivariate Cox model in the training cohort, consisting of 3476 patients from two Korean hospitals, were used to construct the prediction model. External validation was performed using data from 5255 patients in Hong Kong. Results: In the training cohort, HCC occurred in 102 patients during 24,019 person-years of observation (0.43%/year). Risk scores were assigned to cirrhosis (C:3), age ≥50 years (A:2), male sex (M:3) and platelet count <150,000/mm Conclusions: The CAMP-B score (cirrhosis, age ≥50 years, male sex and platelet count <150,000/mm
MeSH term(s)	Humans ; Carcinoma, Hepatocellular/epidemiology ; Male ; Hepatitis B, Chronic/complications ; Liver Neoplasms/epidemiology ; Liver Neoplasms/etiology ; Female ; Middle Aged ; Hepatitis B Surface Antigens/blood ; Retrospective Studies ; Risk Factors ; Adult ; Aged ; Liver Cirrhosis/virology ; Hong Kong/epidemiology ; Republic of Korea/epidemiology ; Risk Assessment ; Platelet Count ; Age Factors
Chemical Substances	Hepatitis B Surface Antigens
Language	English
Publishing date	2024-02-29
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	639012-2
ISSN	1365-2036 ; 0269-2813 ; 0953-0673
ISSN (online)	1365-2036
ISSN	0269-2813 ; 0953-0673
DOI	10.1111/apt.17933
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2206: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito